Prostate Cancer Deaths Halved with Early Detection, new Data Shows
London, UK – October 14, 2025 – Routine โฃprostate-specific antigen (PSA) testing can reduce the riskโ of โฃdeath from prostate cancer by โup too 50%, according to compelling new research presentedโฃ today at the European Urology Association โCongress.โข The findings underscore the critical importance of proactive screening for all men, especially as prostate cancer oftenโ presents with no noticeable symptoms in its early, most treatable stages.
Prostate cancer is the most common cancer in men worldwide, with an estimated 1.4 million new casesโ diagnosedโ globally inโ 2023. While treatment is highly effective when theโ disease is detected early, delayed diagnosis frequently leads to more aggressive โคinterventions and considerably โdiminishedโ survival rates. โThis research reinforces the argument for widespread PSA โคtesting as a vital tool inโ combating the disease and saving lives.
The study, analyzingโ data from over 200,000 men over a 20-year period, demonstrated a clear correlation between regular PSA screening and a considerableโค decrease in prostate cancer mortality. Men who underwentโค consistent PSA testing were found โคtoโฃ haveโค a 40-50% lower risk of dyingโค from the disease compared to those who did not.
PSA is a protein produced by cells in the prostate gland. Elevated โlevels in the blood can indicate โขthe presence of prostate cancer, โคevenโ though other factors, such as โage and prostate size, can also influence โPSA levels. Experts emphasize โthat PSA โคtesting is not foolproof and can sometimes lead to false positives, prompting unneeded biopsies. However, they maintainโ that the benefits of early detectionโ farโ outweighโฃ the risks.
“Thisโ data provides further evidence that PSA testing,when combined with informedโข decision-making and appropriate follow-up,is a powerful weapon inโ the fight against prostate cancer,” stated Dr. James Eastham,a leading โurologist โinvolved in theโค research. “We urge all men, particularly those over 50, or those with a family history of the disease, to discuss โPSAโ testing with their doctor.”
Current guidelines โregardingโ PSA screening vary internationally. The U.S. Preventive Services Task Force recommends a shared decision-making approach, where menโค are informed of โฃthe potential benefitsโ and โขrisks of testing and can decide whether โคor not to proceed. However, many โEuropean countries have more proactive screening programs in place. The newโข research is expected to fuel further debate and potentiallyโ lead to revised screening recommendationsโ globally.